Figure 4.

Lysicamine modulates AKT phosphorylation in thyroid cancer cells. (a) p-AKT was reduced in KTC-2 in a dose-dependent manner after lysicamine treatment. (b) p-AKT was reduced in HTH83 cells with 1.5× IC₅₀ lysicamine treatment. No ERK phosphorylation modulation was observed in both cell lines. Cells were cultured without fetal bovine serum (FBS), and after 24 h, FBS was added alone or combined with DMSO or lysicamine 0.5×, 1×, or 1.5× IC₅₀0. Protein extraction was performed 30 min treatment after. Representative images of two or more biological replicates conducted per cell line are presented.